← Leaderboards
Douglas W.p. Hay
Allinaire Therapeutics, Llc
$238,380
Attributed
$715,140
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$715,140 · 1
By mechanism
R44$715,140 · 1
Top collaborators
- Matthias Clauss1 shared
- Irina Petrache1 shared
Most similar at Allinaire Therapeutics, Llc
Same institution · by research overlap
- Christa Lynn Modery$319,592
Others in their field
Other Emerging Leaders on “Alpha 1-Antitrypsin Deficiency”
- Charlton B Strange · Columbia University Health Sciences$2,966,083
- Allison May Keeler-Klunk · Univ Of Massachusetts Med Sch Worcester$2,714,081
- Dan Wang · Univ Of Massachusetts Med Sch Worcester$2,714,081
- Adel El Boueiz · Brigham And Women'S Hospital$2,605,661
- Simon Horslen · Seattle Children'S Hospital$1,500,894
- Inmaculada Aban · University Of Alabama At Birmingham$1,356,303
Research focus
Alpha 1-Antitrypsin DeficiencyAlveolar DestructionAnimalsAntibodiesApoptosisAutomobile DrivingBacteriophagesBindingBiological MarkersCause Of DeathCellsCessation Of LifeCharacteristicsChronicChronic BronchitisChronic Obstructive Airway DiseaseCigarette SmokeCigarette Smoke-InducedClinical CandidateClinical DataClinical DevelopmentClinical EffectClinically RelevantAffinity